The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety.
Stanley Lyndon
Pharmacopsychiatry March 2026 DOI: 10.1055/a-2647-8030 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Nabilone Tetrahydrocannabinol (THC) Cannabidiol (CBD) Fatty acid amide hydrolase (FAAH) inhibitors |
| Topics | Anxiety PTSD |
| Key findings | The authors argue that targeting the endocannabinoid system, including CB1, CB2, FAAH, and monoacylglycerol lipase, offers a framework for developing better-tolerated PTSD treatments. They cite preclinical evidence that cannabinoids facilitate fear extinction and preliminary human findings that nabilone alleviates trauma-related nightmares and acute cannabinoids modulate amygdala threat reactivity, while cautioning that dosing, sex differences, and THC:CBD ratios remain unresolved and that cannabis self-medication carries risks. |
Abstract
Fear and anxiety perform essential protective roles, yet when they become dysregulated, they can trap trauma survivors in persistent hypervigilance and distress. Post-traumatic stress disorder (PTSD) manifests as intrusive memories, avoidance, and heightened arousal long after the precipitating event. Although current pharmacotherapies - including selective serotonin reuptake inhibitors, adrenergic blockers, benzodiazepines, and atypical antipsychotics - provide relief for some, many patients contend with residual symptoms or intolerable adverse effects. Recent discoveries position the endocannabinoid system as a pivotal regulator of fear acquisition, consolidation, and extinction. Clinical observations of altered anandamide levels and cannabinoid receptor CB₁ upregulation in individuals with severe PTSD underscore the therapeutic potential of restoring endocannabinoid tone. Preclinical studies demonstrate that direct CB₁ agonists, fatty acid amide hydrolase (FAAH) inhibitors, and phytocannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) can facilitate extinction learning and attenuate anxiety-like behaviours. Preliminary human trials report that nabilone alleviates trauma-related nightmares and that acute cannabinoid administration modulates amygdala reactivity to a threat. Yet optimal dosing strategies, sex-specific responses, and ideal THC:CBD ratios remain to be defined. Self-medication with cannabis can offer transient relief but carries a risk of cannabis use disorder and potential worsening of PTSD symptoms. By elucidating molecular targets - including CB₁, CB₂, FAAH, and monoacylglycerol lipase - this review outlines a strategic framework for next-generation cannabinoid-based interventions. Harnessing the endocannabinoid system promises to expand the therapeutic arsenal for PTSD, offering hope for more effective and better-tolerated treatments.
Comparable studies
Other narrative reviews on PTSD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic Psychiatry's Brave New World. | 2020 | Review | |
| Reviewing the Potential of Psychedelics for the Treatment of PTSD | 2020 | Review | |
| Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. | 2016 | Review | |
| MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? | 2018 | Review | |
| Clinical applications of hallucinogens: A review. | 2016 | Review |
Citations in the library
Cites 10
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life Frontiers in Pharmacology May 11, 2017
- The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial PLoS One March 17, 2021
- Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation? Biological Psychiatry July 1, 2021
- Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder. Journal of Affective Disorders September 1, 2020
- Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. Psychopharmacology June 2020
and 5 more in the library